Driving better and safer HER2-specific CARs for cancer therapy
Metrics: PDF 1591 views | HTML 3687 views | ?
Xianqiang Liu1,*, Nan Zhang2,* and Huan Shi3
1Department of Breast and Thyroid Surgery, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
2Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
3Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China
*These authors contributed equally to this work
Huan Shi, email: firstname.lastname@example.org
Keywords: chimeric antigen receptor, HER2, cancer, immunotherapy, toxicity
Received: March 20, 2017 Accepted: April 14, 2017 Published: April 29, 2017
Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from “on-target, off-tumor” recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.